Motivated by our goal to end the increasing incidence of cancers worldwide, we are leveraging new scientific discoveries to develop meaningful therapies against the most aggressive cancers. Our team of drug developers, researchers, scientists, and doctors are focusing on cancers with limited treatment options, including rare and late-stage metastatic cancers.
Mission
Cancer diagnoses are increasing worldwide
According to IARC/WHO, the number of new cancer cases per year will reach 35 million by 2050, a 77% increase from 2022.
25% of cancer deaths are from rare cancers
Collectively, rare cancers make up for 24% of all cancer diagnosis and 25% of cancer deaths due to lack of healthcare options.
The mesothelioma 5-year survival rate is 10% worldwide, 12% in the US and a little over 5% in England.
Penn Medicine / Cancer Research UK
Our Values
Respect: Authentic dialogue and interactions strengthen our partnerships
Versatility: Flexibility and agility allow us to embrace opportunities at the right time
Ingenuity: Inventing original ideas and clever solutions is key to all that we do
Optimism: Resilient and positive in each situation we face